
<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>Sequana Medical</provider_name><provider_url>https://www.sequanamedical.com/nl/</provider_url><title>Transparantiekennisgeving van Aandeelhouders - Sequana Medical</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="A4OA62PoUW"&gt;&lt;a href="https://www.sequanamedical.com/nl/persberichten/transparantiekennisgeving-van-aandeelhouders-3/"&gt;Transparantiekennisgeving van Aandeelhouders&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://www.sequanamedical.com/nl/persberichten/transparantiekennisgeving-van-aandeelhouders-3/embed/#?secret=A4OA62PoUW" width="600" height="338" title="&#x201C;Transparantiekennisgeving van Aandeelhouders&#x201D; &#x2014; Sequana Medical" data-secret="A4OA62PoUW" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script type="text/javascript"&gt;
/* &lt;![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://www.sequanamedical.com/wp-includes/js/wp-embed.min.js
/* ]]&gt; */
&lt;/script&gt;
</html><description>PERSBERICHT GEREGLEMENTEERDE INFORMATIE 13 januari 2025, 17:30 CET Gent, Belgi&#xEB;&nbsp;&#x2013; 13 januari 2025 &#x2013;&nbsp;Sequana Medical NV (Euronext Brussels: SEQUA)&nbsp;(de&nbsp;&#x201C;Vennootschap&#x201D;&nbsp;of&nbsp;&#x201C;Sequana Medical&#x201D;), een pionier in de behandeling van vochtoverbelasting in leveraandoeningen, hartfalen en kanker, kondigt vandaag aan dat zij een transparantiekennisgeving heeft ontvangen met betrekking tot de hieronder vermelde entiteiten, met vermelding van het aantal stemrechten verbonden [&hellip;]</description></oembed>
